Largactil (Chlorpromazine Hydrochloride)

Chlorpromazine works mainly by blocking dopamine D2 receptors in the brain, which reduces dopaminergic activity linked to psychosis. It also antagonises histamine H1, muscarinic, and alpha‑adrenergic receptors, producing sedation, anti‑emetic action, and blood‑pressure lowering effects that together contribute to its therapeutic profile.

The dosage of Largactil is individualized by the prescribing clinician based on the patient’s condition, age, response, and tolerability. Physicians determine the appropriate strength, frequency, and duration, and patients should follow the prescribed regimen without self‑adjusting the dose.

Chlorpromazine is classified as a pregnancy‑category drug with limited data; it should only be used when the potential benefit justifies any possible risk to the fetus. Likewise, it passes into breast milk, so breastfeeding mothers should discuss risks and alternatives with their healthcare provider.

To order Largactil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Largactil belongs to the typical, phenothiazine class of antipsychotics, which are generally less selective than newer atypical agents. It is effective for acute psychosis and agitation but may have a higher incidence of extrapyramidal side effects. Choice of therapy depends on clinical response, side‑effect profile, and individual patient factors.

Largactil should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Largactil is administered orally, typically as a tablet or liquid taken with water. The exact route (with or without food) and timing are determined by the prescriber. Patients should swallow the medication whole and not crush or chew tablets unless specifically instructed.

Serious risks include extrapyramidal symptoms such as dystonia or parkinsonism, neuroleptic malignant syndrome, severe hypotension, cardiac arrhythmias (especially QT prolongation), agranulocytosis, and liver toxicity. Any sudden changes in movement, temperature, blood pressure, or signs of infection should prompt immediate medical evaluation.

Largactil is contraindicated in patients with known hypersensitivity to chlorpromazine or other phenothiazines, those with severe cardiovascular disease prone to hypotension, and individuals with a history of neuroleptic malignant syndrome. Caution is also advised for patients with uncontrolled epilepsy, severe liver impairment, or those taking interacting medications listed under major interactions.